

## Company Overview

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.

## Pipeline

### Neurodegeneration

**NE3107 is the only inhibitor of neuroinflammation and insulin resistance in Phase 3 clinical trials for Alzheimer’s Disease (AD)**

- NE3107 reduced inflammation and insulin resistance in a randomized, double-blinded, placebo-controlled Phase 2 study. Potential to address the two factors described as key drivers of cognitive decline in AD.
- Phase 3 patient enrollment under way; ramping up 45 centers for trial; data readout anticipated by end of 2022.
- \$10+ billion annual peak sales potential.

**NE3107 also being developed for Parkinson’s disease (PD) since neuroinflammation, insulin resistance, and oxidative stress are common features in AD and PD. Remarkable parallels exist between AD and PD with respect to underlying disease pathology**

- NE3107 was equally pro-motoric as levodopa in MPTP marmosets, decreased the severity of levodopa induced dyskinesia (LID), and preserved twice as many neurons when compared to untreated in preclinical studies.
- Phase 2 trial data readout anticipated 2Q22.
- \$3+ billion annual peak sales potential.

| Company             | Exchange:Ticker | Drug Candidate | Clinical Status <sup>1</sup> | Mechanism of action  | Market Cap (\$mm) <sup>2</sup> |
|---------------------|-----------------|----------------|------------------------------|--|--------------------------------|
| BioVie Inc.         | Nasdaq: BIVI    | NE3107         | Phase 3                      | Inhibits ERK/NFkB neuroinflammation<br>Inhibits insulin resistance | \$163                          |
| Cortextyme, Inc.    | Nasdaq: CRTX    | Atuzaginstat   | Phase 2/3                    | Inhibits P. gingivalis toxin                                       | \$2,736                        |
| Cassava Sciences    | Nasdaq: SAVA    | Simufilam      | Phase 2                      | Restores filamin A   | \$2,275                        |
| Athira Pharma       | Nasdaq: ATHA    | ATH-1017       | Phase 2                      | Activates neuron regeneration                                      | \$343                          |
| Vaccinex            | Nasdaq: VCNX    | VX15           | Phase 1/2                    | Ab to SEMA4D neuroinflammation                                     | \$64                           |
| Annovis             | NYSE: ANVS      | ANVS-401       | Phase 1/2                    | Decreases APP & Tau  | \$250                          |
| ImmuneBio           | Nasdaq: INMB    | XPRO1595       | Phase 1                      | dN TNF neuroinflammation   | \$330                          |
| Denali Therapeutics | Nasdaq: DNLI    | DNL788         | preclinical                  | RIPK1 inhibitor, TNFR pathway                                      | \$6,110                        |

<sup>1</sup> As reported in Clinicaltrials.gov on 8/2/21 | <sup>2</sup> Closing value on 10/1/21

**Among competitive molecules exploring neuroinflammation and AD, NE3107 is the only one that:**

- Has published randomized, double-blinded, placebo Phase 2 results potentially suggesting reduction in inflammation and insulin resistance in a major population, and warranting further review in Phase 3.
- Potentially inhibits both overarching mechanisms of AD pathology – inflammation and insulin resistance.
- Potentially inhibits proinflammatory pathways without impacting homeostasis.
- Is in Phase 3 clinical development, which is expected to have topline results by the end of 2022.

### Liver Disease

**BIV201 is the only drug currently in development for refractory ascites, a condition with 50% mortality rate. It has the potential to become first therapy since there are no approved drugs in the US**

- BIV201 is a novel formulation of terlipressin for continuous infusion; Orphan and Fast Track designations received.
- Data from Europe/Asia supports development of BIV201; no drug-related AEs in trials thus far.
- Phase 2b underway with data readout anticipated early 2022. Phase 3 for HRS-AKI planned for 2022.
- \$1.3+ billion global peak sales potential.

## Significant Catalysts

|             | 2021     |    | 2022    |    |    |    | 2023     |        |    |    | 2024                           |    |    |    | 2025 |    |    |    |  |
|-------------|----------|----|---------|----|----|----|----------|--------|----|----|--------------------------------|----|----|----|------|----|----|----|--|
|             | Q3       | Q4 | Q1      | Q2 | Q3 | Q4 | Q1       | Q2     | Q3 | Q4 | Q1                             | Q2 | Q3 | Q4 | Q1   | Q2 | Q3 | Q4 |  |
| Alzheimer's | Phase 3* |    |         |    |    |    | File NDA | Launch |    |    | Trials for global registration |    |    |    |      |    |    |    |  |
| Parkinson's | Phase 2a |    | Phase 3 |    |    |    |          |        |    |    |                                |    |    |    |      |    |    |    |  |
| Ascites     | Phase 2b |    | Phase 3 |    |    |    |          |        |    |    |                                |    |    |    |      |    |    |    |  |
| HRS-AKI     | Phase 3  |    |         |    |    |    |          |        |    |    |                                |    |    |    |      |    |    |    |  |

### BioVie poised for significant catalysts in 2022

- Data read outs from Ascites Phase 2 and Parkinson's Phase 2 anticipated during the first half of 2022.
- Read out from Alzheimer's Phase 3 anticipated by the end of 2022.
- Multiple other efforts underway that may create additional catalysts as early as 4Q21 and will be announced publicly when the company deems appropriate.

## Experienced Leadership Team

- Terren Peizer, Chairman; founded and successfully commercialized several healthcare companies. Chairman of Acuitas Group Holdings, a personal holding company that owns all his portfolio company interests, \$1.5B invested directly into portfolio companies; majority shareholder of BioVie.
- Cuong Do, President & CEO; former Chief Strategy Officer at Merck; a veteran biotech and pharmaceutical entrepreneur, having previously founded Callidus Biopharma (sold to Amicus Therapeutics) and M6P Therapeutics.
- Jonathan Adams, EVP Liver Disease Programs; 30+ years of biopharma experience, including technology commercialization, finance, global product launches, drug marketing and sales force management.
- Clarence Ahlem, EVP Neuroscience Product Development– Neurodegenerative Disease; 35+ years of experience in developing NE3107 and related assets with accomplished track record in the biopharma industry.
- Chris Reading PhD, EVP Neuroscience R&D – Neurodegenerative Disease; 40+ years in biopharma; former CSO of Hollis-Eden Pharmaceuticals; MD Anderson Cancer Center; 130+ peer-reviewed publications.
- J. Wendy Kim, CFO; 35 years in finance/accounting with 22 years combined experience at KPMG and BDO; as CFO managed corporate finance and operations and closed M&A transactions and secured financings.

## Market Data

| BioVie Inc   NASDAQ: BIVI |          |              |            |             |       |               |                    |            |
|---------------------------|----------|--------------|------------|-------------|-------|---------------|--------------------|------------|
| Fiscal Year               | Industry | Recent Price | Market Cap | Shares Out. | Float | Insiders Own. | Avg. Vol. (90-day) | Cash (mrq) |
| June                      | Biotech  | \$5.30       | \$132.5M   | 25.0M       | 5.1M  | 79.4%         | 91,247             | \$20.5M    |

*As of December 22, 2021*

### Corporate Headquarters

2120 Colorado Avenue  
Suite 230  
Santa Monica, CA 90404

### Company Website

[biovieinc.com](http://biovieinc.com)

Tel: 312-283-5793  
[info@biovieinc.com](mailto:info@biovieinc.com)

### Stock Transfer Agent

West Coast Stock Transfer  
721 N. Vulcan Ave., First Floor  
Encinitas, CA 92024  
619-664-4780